Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Abstract Molnupiravir (MK‐4482) is an oral prodrug of the antiviral ribonucleoside analog, N‐
hydroxycytidine (NHC), which has activity against RNA viruses, including severe acute …

Background Evidence evaluating real-world effectiveness of oral antivirals against Omicron
variants is lacking. Methods An unselected, territory-wide cohort of all initially non …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Oral therapies for the early treatment of COVID-19 may prevent disease progression and
health system overcrowding. A new oral therapeutic named molnupiravir has been …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has emerged to cause
pandemic respiratory disease in the past 2 years, leading to significant worldwide morbidity …

Viral clearance, antibody response and the mutagenic effect of molnupiravir has not been
elucidated in at-risk populations. Non-hospitalised participants within 5 days of SARS-CoV-2 …

The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …

Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …